Analysts predict that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will announce earnings per share (EPS) of ($1.15) for the current quarter, according to Zacks. Zero analysts have made estimates for Axovant Gene Therapies earnings. The lowest EPS estimate is ($1.39) and the highest is ($0.76). Axovant Gene Therapies posted earnings per share of ($2.24) during the same quarter last year, which indicates a positive year-over-year growth rate of 48.7%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Axovant Gene Therapies will report full-year earnings of ($4.25) per share for the current fiscal year, with EPS estimates ranging from ($5.59) to ($3.47). For the next fiscal year, analysts expect that the company will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.35) to ($2.89). Zacks earnings per share calculations are an average based on a survey of sell-side analysts that cover Axovant Gene Therapies.

Axovant Gene Therapies (NASDAQ:AXGT) last issued its quarterly earnings data on Friday, August 9th. The company reported ($1.23) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.11.

Several large investors have recently added to or reduced their stakes in AXGT. BlackRock Inc. acquired a new position in shares of Axovant Gene Therapies in the second quarter valued at approximately $1,482,000. Marshall Wace LLP acquired a new position in Axovant Gene Therapies during the first quarter worth $272,000. Jane Street Group LLC grew its holdings in Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. 13.76% of the stock is currently owned by institutional investors and hedge funds.

Axovant Gene Therapies stock traded down $0.01 during mid-day trading on Thursday, reaching $6.29. 38,700 shares of the companys stock were exchanged, compared to its average volume of 118,874. The company has a fifty day moving average of $6.55 and a 200-day moving average of $5.80. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 0.60. The company has a market cap of $143.40 million, a P/E ratio of -0.78 and a beta of 1.25. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Recommended Story: What are earnings reports?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

See original here:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Expected to Post Earnings of -$1.15 Per Share - Mitchell Messenger

Comments are closed.